Exosomes as drug carriers for cancer therapy and challenges regarding exosome uptake - 18/06/20
pages | 9 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Highlights |
• | Exosomes as carriers improve the effect and safety of drugs. |
• | Exosomes as carriers inhibit tumors by delivering miRNAs, proteins and chemical drugs. |
• | Elucidating the process of uptake promotes the application of exosome-based therapy. |
Abstract |
With the development of biomedicine, exosomes are rapidly developing as a new therapy for tumors. As biological carriers, exosomes possess biological activity and can transport their contents between cells. The contents are natural or artificially loaded with biomolecules or chemical drugs. Exosomes deliver biomolecules or chemical drugs into the pathological sites of recipient, which can effectively inhibit the progression of tumors. However, the treatments of tumors through the delivery of exosomes are not sufficiently accurate or efficient, and various challenges need to be overcome. Exosomes from different cell sources possess different characteristics, as well as different specificity for various cells. In the future, for the promotion and application of exosomes, it is of great significance to understand how to select appropriate exosomes loaded with biomolecules or chemical drugs for different tumors types, and how to deliver exosomes to recipient cells accurately and efficiently. This review introduces the application and challenges of exosomes as delivery carriers in tumors.
Le texte complet de cet article est disponible en PDF.Abbreviations : miRNA, MVB, HCC, PDAC, CRC, DC, GPI, SIRPα, VAMP, FLIM
Keywords : Exosomes, Cancer therapy, Drug delivery, Exosome uptake
Plan
Vol 128
Article 110237- août 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?